MX2009012891A - Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n. - Google Patents
Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n.Info
- Publication number
- MX2009012891A MX2009012891A MX2009012891A MX2009012891A MX2009012891A MX 2009012891 A MX2009012891 A MX 2009012891A MX 2009012891 A MX2009012891 A MX 2009012891A MX 2009012891 A MX2009012891 A MX 2009012891A MX 2009012891 A MX2009012891 A MX 2009012891A
- Authority
- MX
- Mexico
- Prior art keywords
- binding proteins
- antigen
- aureus
- orf0657n
- proteins targeting
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a proteínas de unión a antígeno que se unen a una región que se ha encontrado que tiene un epítope que puede ser dirigido para proveer protección contra infección por S. aureus; la región se designa aquí como la región objetivo "CS-D7"; la región objetivo CS-D7 provee un epítope de S. aureus ORF0657n que puede ser dirigido para reducir la probabilidad o severidad de una infección por S. aureus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93278807P | 2007-05-31 | 2007-05-31 | |
US799807P | 2007-12-17 | 2007-12-17 | |
PCT/US2008/006791 WO2009029132A2 (en) | 2007-05-31 | 2008-05-29 | Antigen-binding proteins targeting s. aureus orf0657n |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009012891A true MX2009012891A (es) | 2009-12-10 |
Family
ID=40380548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009012891A MX2009012891A (es) | 2007-05-31 | 2008-05-29 | Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20100166772A1 (es) |
EP (1) | EP2164869A2 (es) |
JP (1) | JP2010528607A (es) |
KR (1) | KR20100021577A (es) |
CN (1) | CN101679516B (es) |
AU (1) | AU2008294038A1 (es) |
BR (1) | BRPI0811193A2 (es) |
CA (1) | CA2687681A1 (es) |
IL (1) | IL201906A0 (es) |
MX (1) | MX2009012891A (es) |
RU (1) | RU2009149294A (es) |
WO (1) | WO2009029132A2 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110091480A1 (en) * | 2006-01-27 | 2011-04-21 | Brown Martha J | Antigen-Binding Proteins Targeting S. Aureus Orf0657n |
CA2697538C (en) | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
KR20170102039A (ko) | 2009-04-03 | 2017-09-06 | 유니버시티 오브 시카고 | 단백질 A(SpA) 변이체와 관련된 조성물 및 방법 |
CN109248313B (zh) | 2009-04-14 | 2023-01-17 | 葛兰素史密丝克莱恩生物有限公司 | 用于免疫接种以抵御金黄色葡萄球菌的组合物 |
CA2779798C (en) | 2009-09-30 | 2019-03-19 | Novartis Ag | Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides |
WO2011049798A1 (en) * | 2009-10-20 | 2011-04-28 | Merck Sharp & Dohme Corp. | Use of mixed mode chromatography for the capture and purification of basic antibody products |
AU2010310919B2 (en) | 2009-10-30 | 2015-05-07 | Glaxosmithkline Biologicals S.A. | Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
KR20130093084A (ko) | 2010-07-02 | 2013-08-21 | 더 유니버시티 오브 시카고 | 단백질 A(SpA) 변이체와 관련된 조성물 및 방법 |
SI2673373T1 (sl) * | 2011-02-08 | 2019-03-29 | Medimmune, Llc | Protitelesa, ki specifično vežejo alfa toksin Staphylococcus aureus in postopki uporabe |
CN102649817A (zh) * | 2011-02-24 | 2012-08-29 | 复旦大学 | 一种抑制细菌生物膜形成的单克隆抗体 |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
WO2013096948A1 (en) | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
KR102100009B1 (ko) | 2016-05-04 | 2020-04-10 | 이길봉 | 3축 트레일러의 조향장치 |
KR20170003596U (ko) | 2017-06-16 | 2017-10-17 | 배경률 | 자동차용 스노우 체인 |
SG11202001160XA (en) * | 2017-09-29 | 2020-03-30 | Regeneron Pharma | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6916605B1 (en) * | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
US7250494B2 (en) | 1998-06-15 | 2007-07-31 | Biosynexus Incorporated | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
KR101287395B1 (ko) * | 2000-06-16 | 2014-11-04 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 면역특이적으로 BLyS에 결합하는 항체 |
US7138496B2 (en) * | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
BR0207068A (pt) * | 2001-01-26 | 2004-12-21 | Inhibitex Inc | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus |
AU2002365978A1 (en) * | 2001-11-19 | 2003-06-10 | Applied Molecular Evolution, Inc. | Tumor specific monoclonal antibodies |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2004258979B2 (en) * | 2003-07-24 | 2007-12-06 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against Staphylococcus aureus |
US20070134263A1 (en) | 2004-02-18 | 2007-06-14 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphyloococcus aureus |
US20070172498A1 (en) | 2004-02-27 | 2007-07-26 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphyloococcus aureus |
AU2005247435A1 (en) | 2004-05-25 | 2005-12-08 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against Staphylococcus aureus |
AU2005287145A1 (en) | 2004-09-17 | 2006-03-30 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against Staphylococcus aureus |
JP2008532483A (ja) | 2005-01-21 | 2008-08-21 | メルク エンド カムパニー インコーポレーテッド | スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド |
CN1320125C (zh) * | 2005-09-28 | 2007-06-06 | 兰州生物制品研究所 | 一种单克隆抗体的制备方法及其应用 |
US20110091480A1 (en) * | 2006-01-27 | 2011-04-21 | Brown Martha J | Antigen-Binding Proteins Targeting S. Aureus Orf0657n |
MX2008014978A (es) * | 2006-06-06 | 2008-12-09 | Crucell Holland Bv | Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas. |
EP3018142A1 (en) * | 2006-06-06 | 2016-05-11 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
-
2008
- 2008-05-29 CA CA002687681A patent/CA2687681A1/en not_active Abandoned
- 2008-05-29 US US12/601,933 patent/US20100166772A1/en not_active Abandoned
- 2008-05-29 KR KR1020097024900A patent/KR20100021577A/ko not_active Application Discontinuation
- 2008-05-29 MX MX2009012891A patent/MX2009012891A/es active IP Right Grant
- 2008-05-29 JP JP2010510333A patent/JP2010528607A/ja active Pending
- 2008-05-29 BR BRPI0811193-6A2A patent/BRPI0811193A2/pt not_active IP Right Cessation
- 2008-05-29 RU RU2009149294/10A patent/RU2009149294A/ru not_active Application Discontinuation
- 2008-05-29 WO PCT/US2008/006791 patent/WO2009029132A2/en active Application Filing
- 2008-05-29 CN CN2008800176016A patent/CN101679516B/zh not_active Expired - Fee Related
- 2008-05-29 EP EP08828478A patent/EP2164869A2/en not_active Withdrawn
- 2008-05-29 AU AU2008294038A patent/AU2008294038A1/en not_active Abandoned
-
2009
- 2009-11-03 IL IL201906A patent/IL201906A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009029132A2 (en) | 2009-03-05 |
WO2009029132A3 (en) | 2009-05-14 |
US20100166772A1 (en) | 2010-07-01 |
CA2687681A1 (en) | 2009-03-05 |
CN101679516B (zh) | 2013-11-13 |
EP2164869A2 (en) | 2010-03-24 |
KR20100021577A (ko) | 2010-02-25 |
AU2008294038A1 (en) | 2009-03-05 |
BRPI0811193A2 (pt) | 2014-11-11 |
CN101679516A (zh) | 2010-03-24 |
IL201906A0 (en) | 2010-06-16 |
RU2009149294A (ru) | 2011-07-10 |
JP2010528607A (ja) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009012891A (es) | Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n. | |
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
UA111818C2 (uk) | Антитіло проти csf-1r | |
UA117901C2 (uk) | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування | |
PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
MX2013010268A (es) | Anticuerpos anti-ctla4 humanizados. | |
BR112012019098A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
BR112013020086A2 (pt) | anticorpos que se ligam especificamente à alfa-toxina de staphylococcus aureus e métodos de utilização | |
WO2011119979A3 (en) | Antibodies to muc16 and methods of use thereof | |
EA201000903A1 (ru) | Антитела к pcrv-антигену pseudomonas aeruginosa | |
WO2009112245A9 (en) | Antibody against the csf-1 r | |
BR112014002758A2 (pt) | composições para cuidados pessoais contendo zinco piritiona submetido à secagem | |
WO2008097439A3 (en) | Anti-autoimmune antibodies for treatment of pemphigus | |
WO2011004028A3 (en) | Tlr3 binding agents | |
WO2012018767A3 (en) | Antibodies directed against il-17 | |
WO2009114560A3 (en) | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections | |
UA107592C2 (uk) | Композиція для боротьби з захворюваннями рослин і її застосування | |
BRPI1010911A2 (pt) | "anticorpos ou fragmentos destes direcionados contra um epitopo de staphylococcus aureus" | |
EA201070826A1 (ru) | Антитела против pcrv | |
NZ702282A (en) | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease | |
MX2011009100A (es) | Anticuerpo humanizado pcrv que tiene actividad anti-pseudomonal. | |
WO2012031260A3 (en) | Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
HC | Change of company name or juridical status | ||
FG | Grant or registration | ||
GB | Transfer or rights | ||
HC | Change of company name or juridical status |